| Year |
Citation |
Score |
| 2020 |
Sui J, Jiao J, Sun Y, Liu J, Bastero R, Koch G. Evaluation of alternative confidence intervals to address non-inferiority through the stratified difference between proportions. Pharmaceutical Statistics. PMID 32820592 DOI: 10.1002/Pst.2063 |
0.353 |
|
| 2020 |
Yu J, Koch G. Randomization-Based Methods for Treatment Comparisons for Dichotomous Outcomes for Multiple Anatomical Regions Statistics in Biopharmaceutical Research. 1-7. DOI: 10.1080/19466315.2020.1750471 |
0.344 |
|
| 2019 |
Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G. Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures. Journal of Biopharmaceutical Statistics. 1-14. PMID 31829826 DOI: 10.1080/10543406.2019.1696355 |
0.355 |
|
| 2019 |
Wiener LE, Ivanova A, Li S, Silverman RK, Koch GG. Randomization-based analysis of covariance for inference in the sequential parallel comparison design. Journal of Biopharmaceutical Statistics. 1-18. PMID 31304861 DOI: 10.1080/10543406.2019.1633660 |
0.375 |
|
| 2019 |
Wang D, Robieson W, Zhao J, Wiener C, Koch G. Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disorders. Pharmaceutical Statistics. PMID 30697912 DOI: 10.1002/Pst.1931 |
0.312 |
|
| 2019 |
Cotter O, Davison BA, Koch G, Senger S, Metra M, Voors AA, Mebazza A, Nielsen OW, Chioncel O, Pang P, Greenberg BH, Maggioni A, Sato N, Teerlink JR, Cotter G. 4329Mega-studies in heart failure, effect dilution in examination of new therapies European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0166 |
0.344 |
|
| 2018 |
George DJ, Pantuck AJ, Motzer RJ, Ravaud A, Escudier B, Staehler MD, Serfass L, Krishnaswami S, Casey M, Lechuga M, Koch G, Figlin RA. S-TRAC trial: Sensitivity analyses of disease-free survival (DFS). Journal of Clinical Oncology. 36: 633-633. DOI: 10.1200/Jco.2018.36.6_Suppl.633 |
0.326 |
|
| 2017 |
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. The New England Journal of Medicine. PMID 29105594 DOI: 10.1056/Nejmoa1710030 |
0.333 |
|
| 2017 |
Ouyang J, Carroll KJ, Koch G, Li J. Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study. Pharmaceutical Statistics. PMID 28470952 DOI: 10.1002/Pst.1808 |
0.332 |
|
| 2017 |
Lam D, Koch GG, Preisser JS, Saville BR, Hussey MA. Randomization-based adjustment of multiple treatment hazard ratios for covariates with missing data. Journal of Biopharmaceutical Statistics. 1-14. PMID 28281895 DOI: 10.1080/10543406.2017.1289954 |
0.642 |
|
| 2017 |
Sun H, Kawaguchi A, Koch G. Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomes. Pharmaceutical Statistics. PMID 28074600 DOI: 10.1002/Pst.1799 |
0.384 |
|
| 2016 |
Fan C, Zhang D, Wei L, Koch G. Methods for Missing Data Handling in Randomized Clinical Trials With Nonnormal Endpoints With Application to a Phase III Clinical Trial Statistics in Biopharmaceutical Research. 8: 179-193. DOI: 10.1080/19466315.2016.1142890 |
0.384 |
|
| 2015 |
Luo X, Li M, Wu C, Xu Q, Chen G, Dornseif BE, Renschler MF, Koch G. A Proposed Approach For Analyzing Post Study Therapy Effect In Survival Analysis. Journal of Biopharmaceutical Statistics. PMID 26247582 DOI: 10.1080/10543406.2015.1074916 |
0.318 |
|
| 2015 |
Wang SJ, Bretz F, Dmitrienko A, Hsu J, Hung HM, Koch G, Maurer W, Offen W, O'Neill R. Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel. Statistics in Medicine. PMID 26112381 DOI: 10.1002/Sim.6561 |
0.353 |
|
| 2015 |
Hussey M, Koch GG, Preisser J, Saville BR. Nonparametric Randomization-Based Covariate Adjustment for Stratified Analysis of Time-to-Event or Dichotomous Outcomes. Journal of Biopharmaceutical Statistics. PMID 26101805 DOI: 10.1080/10543406.2015.1052483 |
0.624 |
|
| 2014 |
El-Khorazaty JA, Koch G, Preisser J. The iterative proportional fitting algorithm for adjusted agreement in a non-inferiority diagnostic clinical trial. Pharmaceutical Statistics. 13: 173-8. PMID 24715653 DOI: 10.1002/Pst.1614 |
0.334 |
|
| 2013 |
Hinderliter AL, Routledge FS, Blumenthal JA, Koch G, Hussey MA, Wohlgemuth WK, Sherwood A. Reproducibility of blood pressure dipping: relation to day-to-day variability in sleep quality. Journal of the American Society of Hypertension : Jash. 7: 432-9. PMID 23850195 DOI: 10.1016/J.Jash.2013.06.001 |
0.589 |
|
| 2013 |
Wang SJ, Bretz F, Dmitrienko A, Hsu J, Hung HM, Huque M, Koch G. Panel forum on multiple comparison procedures: a commentary from a complex trial design and analysis plan. Biometrical Journal. Biometrische Zeitschrift. 55: 275-93. PMID 23553537 DOI: 10.1002/Bimj.201200047 |
0.352 |
|
| 2013 |
Li S, Hussey MA, Schwartz TA, Koch GG. A multistage analysis strategy for a clinical trial to assess successively more stringent criteria for a primary endpoint with a low event rate. Pharmaceutical Statistics. 12: 65-73. PMID 23424092 DOI: 10.1002/Pst.1554 |
0.624 |
|
| 2013 |
Hussey MA, Koch GG, Preisser JS, Saville BR. Analysis of Matched Studies With Dichotomous Outcomes Using Nonparametric Randomization-Based Analysis of Covariance Statistics in Biopharmaceutical Research. 5: 194-203. DOI: 10.1080/19466315.2013.769896 |
0.615 |
|
| 2011 |
Gray LD, Hussey MA, Larson BM, MacHlus KR, Campbell RA, Koch G, Ezban M, Hedner U, Wolberg AS. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma Thrombosis Research. 128: 570-576. PMID 21561645 DOI: 10.1016/J.Thromres.2011.04.009 |
0.589 |
|
| 2010 |
Hasford J, Bramlage P, Koch G, Lehmacher W, Einhäupl K, Rothwell PM. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. Journal of Clinical Epidemiology. 63: 1298-304. PMID 20172690 DOI: 10.1016/J.Jclinepi.2009.10.009 |
0.324 |
|
| 2010 |
Quan H, Wu Y, Ren H, Seko N, Bizet F, Koch G. Benefit-Risk Assessments in Dose-Finding Trials Statistics in Biopharmaceutical Research. 2: 153-164. DOI: 10.1198/Sbr.2009.0069 |
0.321 |
|
| 2008 |
Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and Drug Safety. 17: 769-81. PMID 18613278 DOI: 10.1002/Pds.1615 |
0.321 |
|
| 2008 |
Dann RS, Koch GG. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials. Pharmaceutical Statistics. 7: 130-41. PMID 17526060 DOI: 10.1002/pst.287 |
0.735 |
|
| 2007 |
Felson D, Aletaha D, Anderson J, Bathon J, Boers M, Bombardier C, Choi H, Dougados M, Furst D, Koch G, Landewé R, LaValley M, Michaud K, Paulus H, Pincus T, et al. A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response Arthritis Care and Research. 57: 193-202. PMID 17330293 DOI: 10.1002/Art.22552 |
0.331 |
|
| 2005 |
Dann RS, Koch GG. Review and evaluation of methods for computing confidence intervals for the ratio of two proportions and considerations for non-inferiority clinical trials. Journal of Biopharmaceutical Statistics. 15: 85-107. PMID 15702607 DOI: 10.1081/Bip-200040844 |
0.736 |
|
| 2005 |
Kong L, Koch G, Liu T, Wang H. Performance of some multiple testing procedures to compare three doses of a test drug and placebo Pharmaceutical Statistics. 4: 25-35. DOI: 10.1002/Pst.148 |
0.317 |
|
| 2005 |
Somerville M, Wilson T, Koch G, Westfall P. Evaluation of a weighted multiple comparison procedure Pharmaceutical Statistics. 4: 7-13. DOI: 10.1002/Pst.136 |
0.303 |
|
| 2004 |
Pathman DE, Konrad TR, Dann R, Koch G. Retention of primary care physicians in rural health professional shortage areas. American Journal of Public Health. 94: 1723-9. PMID 15451741 DOI: 10.2105/Ajph.94.10.1723 |
0.693 |
|
| 2004 |
Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort J. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis Annals of the Rheumatic Diseases. 63: 931-939. PMID 15082468 DOI: 10.1136/Ard.2003.020313 |
0.341 |
|
| 2003 |
Müller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, Lefkowitz M. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. Journal of Clinical Epidemiology. 56: 310-6. PMID 12767407 DOI: 10.1016/S0895-4356(03)00027-1 |
0.344 |
|
| 2003 |
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, Vitiello B, Severe J, Casat C, Kolker J, Feeny N, Findling R, Stull S, ... ... Koch G, et al. Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods Journal of the American Academy of Child and Adolescent Psychiatry. 42: 531-542. PMID 12707557 DOI: 10.1097/01.Chi.0000046839.90931.0D |
0.313 |
|
| 2003 |
Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 995-1003. PMID 12700715 DOI: 10.1038/Sj.Npp.1300157 |
0.32 |
|
| 2003 |
Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis and Rheumatism. 48: 625-30. PMID 12632413 DOI: 10.1002/Art.10824 |
0.321 |
|
| 2003 |
Drossman DA, Diamant N, Toner B, Whitehead W, Dalton C, Duncan S, Akman D, Frusciante K, Meyer K, Blackman C, Hu Y, Jia H, Li Z, Morris C, Koch G, et al. A multi-center randomized trial of desipramine (DES) vs. placebo (PLA) in moderate to severe functional bowel disorder (FBD) Gastroenterology. 124: A30. DOI: 10.1016/S0016-5085(03)80146-4 |
0.302 |
|
| 2002 |
Witjes WP, de la Rosette JJ, van den Berg-Segers A, Colongo D, Koch G, Zlotta AR, Colau A, de Wildt MJ, Wijkstra H. Computerised assessment of maximum urinary flow: an efficient, consistent and valid approach. European Urology. 41: 206-13; discussion 2. PMID 12074410 DOI: 10.1016/S0302-2838(01)00037-9 |
0.335 |
|
| 1999 |
Hinderliter AL, Willis PW, Long W, Clarke WR, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Biosblanc B, Koch G, Li S, Clayton LM, Jöbsis MM, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. The American Journal of Cardiology. 84: 481-4, A10. PMID 10468096 DOI: 10.1016/S0002-9149(99)00342-2 |
0.307 |
|
| 1999 |
Hadgu A, Koch G. Application of generalized estimating equations to a dental randomized clinical trial. Journal of Biopharmaceutical Statistics. 9: 161-178. PMID 10091916 DOI: 10.1081/Bip-100101006 |
0.378 |
|
| 1997 |
Tulloch JFC, Phillips C, Koch G, Proffit WR. The effect of early intervention on skeletal pattern in Class II malocclusion: a randomized clinical trial. American Journal of Orthodontics and Dentofacial Orthopedics. 111: 391-400. PMID 9109584 DOI: 10.1016/S0889-5406(97)80021-2 |
0.327 |
|
| 1993 |
Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley C, Moreadith C, Phillips J, Vander Elst E, Koch G. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. Journal of Hypertension. 11: 217-21. PMID 8385183 DOI: 10.1097/00004872-199302000-00015 |
0.322 |
|
| 1991 |
Curtis JL, Houghton JL, Patterson JH, Koch G, Bradley DA, Adams KF. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing American Heart Journal. 121: 1655-1664. PMID 2035380 DOI: 10.1016/0002-8703(91)90009-7 |
0.302 |
|
| 1991 |
Gillings D, Koch G. The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials Drug Information Journal. 25: 411-424. DOI: 10.1177/009286159102500311 |
0.339 |
|
| 1987 |
Gillings D, Koch G, Reich T, Stager WJ. Another Look at the Pentoxifylline Efficacy Data for Intermittent Claudication The Journal of Clinical Pharmacology. 27: 601-609. PMID 3655008 DOI: 10.1002/J.1552-4604.1987.Tb03072.X |
0.342 |
|
| Show low-probability matches. |